Renaissance of amantadine in the treatment of Parkinson's disease.
Blanchet
Pierre J
PJ
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Metman
Leo Verhagen
LV
Chase
Thomas N
TN
D000547:Amantadine / Q000008:administration & dosage* / Q000009:adverse effects*; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000517:prevention & control; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D007980:Levodopa; D000547:Amantadine